| Study Name | Description | Trial Category | Trial SubCategory |
|---|---|---|---|
| RTOG 1216 | This study is for patients with squamous cell cancer of the head and neck. It looks at after surgery adding radiation to the standard of care chemotherapy to treat the cancer. | Cancer | Head & Neck |
| S1900G (LUNGMAP substudy) | The purpose of this study is to determine if adding ramucirumab in combination with capmatinib and osimertinib is effective in treating patients with Stage 4 or recurrent non-small cell lung cancer. | Cancer | Metastatic Non-Small Cell Lung |
| S1900J (LUNGMAP substudy) | The purpose of this study is see if Amivanatamab is effective in treating patients with MET-Amplification Positive Stage 4 or recurrent non-small cell lung cancer. | Cancer | Metastatic Non-Small Cell Lung |
| S1900K (LUNGMAP substudy) | The purpose of this study is to determine if the use of Tepotinib with or without Ramucirumab is effective in patients with MET Exon 14 skipping positive stage 4 or recurrent non-small cell lung cancer (NSCLC).(LUNGMAP sub-study) | Cancer | Metastatic Non-Small Cell Lung |
| S2312 | This study is for patients with metastatic prostate cancer. It looks at using Cabazitaxel with or without carboplatin in patients with castrate-resistant prostate cancer. | Cancer | Prostate |
| S2303 | This study is for patients who have progressed on standard of care treatment for gastric or esophageal cancer. The study looks at adding Nivolumab to 2nd line treatment to see if it improves outcomes. | Cancer | Gastric or Esophageal |
| Basic | The purpose of this study is to test if different mobile or wearable devices can measure how much time a person's heart is in atrial fibrillation over a period of 4 months. | Heart & Vascular | Atrial Fibrillation |
| Picasso | The study is trying to assess the safety and efficacy of fixing the narrowing in your carotid artery using a stent versus using a balloon or suction method when performed at the same time as the mechanical thrombectomy. | Neurosciences | Stroke |
| EA5221 | The purpose of this study is to determine in the older adult population if immunotherapy alone is better than immunotherapy + chemotherapy. Patients must be 70+ with diagnosis of Non-Small Cell Lung Cancer. | Cancer | Non-Small Cell Lung Cancer |
| NRG CC011 | This study is for patients with stage 1-3 breast cancer. Patient must be > 6 months to 5 years out from treatment and experiencing symptoms of brain fog. The study using cognitive training to try to improve brain fog symptoms. | Cancer | Breast |
| Librexia ACS | The purpose of this study is to see if an experimental drug, called milvexian is safe, effective and useful in reducing risk of developing blood clots, stroke, or another heart attack among subjects with a recent heart attack or angina (chest pain) episode. An experimental drug is one that is not approved by the United States Food and Drug Administration (FDA). | Heart & Vascular | Atrial Fibrillation |
| A032103 | The purpose of this study is to use central DNA testing to monitor recurrance in patients with urothelial cancer. You must have had a radical cysectomy and lymph node dissection with no evidence of residual cancer. | Cancer | Urothelial |
| EAY191-N5 | This study is for patient's who have HER2+ gynecologic cancers or other solid tumors. Cannot have breast cancer. You must have recurrent disease or progressed on treatment. | Cancer | Her2+ Solid Tumors |
| S2101 | This study is for patients with Stage III or IV, unresectable, recurrent, or metastatic melanoma. This study uses Nivolumab and Cabozantinib to treat patients. | Cancer | Melanoma |
| SOUL Music | This is a multicenter prospective trial with randomized and observational cohorts assessing patient-reported outcomes and unplanned healthcare utilization following ureteroscopic treatment of renal and ureteral stones, with placement versus omission of a ureteral stent. Eligible participants in the randomization trial will be randomized to ureteroscopy with stent placement or stent omission. Eligible participants that consent to the observational only cohort will complete surveys and the treating physicians will decide the treatment options for the participants. | Surgery | Urinary Stone Disease |
| S2013 | The purpose of this study is the look at the side effects of immunotherapy treatment. You must be starting immunotherapy in combinationchemo. You must have a solid tumor. You must have small cell lung cancer, non-small cell lung cancer, triple negative breast cancer or gastroesophageal cancer. | Cancer | Solid Tumors |
| NRG-BR009 | The purpose of this study is treat breast cancer after surgery. You must have estrogen positive breast cancer and an oncotype score ≤25. This study looks at adding chemotherapy to the standard treatment of ovarian function suppression and aromatase inhibitor. | Cancer | Breast |
| GU012 | The purpose of this study is to compare standard immunotherapy with immunotherapy and radiation. You must be diagnosed with metastatic renal cell cancer and have not had surgery for this cancer. | Cancer | Metastatic Renal Cell |
| S2209 | This study is for frail-intermediately fit newly diagnosed multiple myeloma patients. Your current lab values will be used to determine if you qualify for this study. This study compares different chemo regimens to determine the effectiveness of them. | Cancer | Multiple Myeloma |
| A031702 | The purpose of this study is to look at the effectineness of cabozantinib combined with nivolumab and ipilimubmab. You must be diagnosed with a rare genitourinary tumor of the kidney, bladder, ureters or penis. | Cancer | Rare Genitourinary |
| A031902 | The purpose of this study is to evaluate progression free survival and overall survival with the use of enzalutamide and rucaparib vs enzalutamide alone. You must be diagnosed with metastatic castration-resistant prostate cancer. This must be your first treatment for your metastatic cancer. | Cancer | Metastatic Prostate |
| A081801 (sub study A151216) | The purpose of this study is to compare disease free survival when adding immunotherapy to initial chemotherapy vs immunotherapy only in maintenance therapy. You must be diagnosed with stage 2 or stage 3 non-small cell lung cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| A212102 | This is a study looking at determining effectiveness of a multicancer early dectection blood test. Participants are healthy subjects, those with a known cancer diagnosis, and those with high suspicion of cancer. | Cancer | All tumor types |
| EA5182 | This study is comparing Osimertinib and Bevacizumab vs Osimertinib alone as first-line treatment for patients with metastatic EGFR mutant Non-Small Cell Lung Cancer (NSCLC). You must be diagnosed with stage 3 or 4 NSCLC. | Cancer | Non-Small Cell Lung |
| EAA173 | The purpose of this study is determine if dararumumab enhances the effectiveness of revlimid in patients with smoldering myeloma. You must be diagnosed with asymptomatic high risk smoldering multiple myeloma. | Cancer | Smoldering Myeloma |
| EAA181 | The purpose of this study is to determine what consolidation regimen is most effective. Patients cannot get stem cell transplant until first relapse or later. You must have newly diagnosed multiple myeloma (MM). | Cancer | Multiple Myeloma |
| EAY191 ComboMATCH | The purpose of this study is to find targeted therapy for specific gene mutations in metastatic or advanced cancer. You must have progressed on standard of care treatment or have a cancer which has no standard of care treatment. If select mutations are found you may be eligible for a sub-study. | Cancer | Genomics |
| EAY191-E4 ComboMATCH | The purpose of this study is to determine the effectiveness of nilotinib and paclitaxel in patients with prior taxane treated solid tumors. You must have had at least one prior line of therapy in the metastatic setting. | Cancer | Solid Tumors |
| ISPY 2 | This study uses the type of breast cancer you are diagnosed with to determine what treatment you are given. You must be diagnosed with stage 2 or stage 3 breast cancer. This study requires regular MRI's. | Cancer | Breast |
| NRG-GI008 | The purpose of this study to use blood draws looking at the tumor DNA in the blood to determine need for chemotherapy. You must be diagnosed with stage 3 colon cancer. | Cancer | Colon |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.